Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Becker’s Healthcare -- Spine and Orthopedic Podcast

Jeffrey Singerman, Administrator and COO, Manhattan Endoscopy Center

30 Nov 2025

6 min duration
1069 words
3 speakers
30 Nov 2025
Description

This episode recorded live at Becker’s 31st Annual The Business and Operations of ASCs features Jeffrey Singerman, Administrator and COO, Manhattan Endoscopy Center. He discusses key market forces driving ASC growth, the emerging impact of AI on clinical and administrative functions, and how partnerships can strengthen recruitment, staffing, and long term sustainability.

Audio
Transcription

Chapter 1: What is the main topic discussed in this episode?

0.031 - 21.583 Unknown

Looking for a solution that helps alleviate administrative tasks for your staff and also helps your patients cover their out-of-pocket healthcare expenses? Find what you're looking for from CareCredit. Because CareCredit is a credit card and more. It's a helping hand for staff and a flexible payment solution for patients. For over 30 years, CareCredit, a synchrony solution,

0

21.563 - 35.286 Unknown

has offered patients a credit card with promotional financing options to get the care they want while helping staff do what they do best, provide care. To learn more, visit carecredit.com forward slash Becker's podcast.

0

Chapter 2: What are the significant trends driving ASC market growth?

35.722 - 54.502 Grace Lynn Keller

This is Grace Lynn Keller with the Becker's Healthcare Podcast, and we are recording live at the 31st Annual Business and Operations of ASCs. I'm currently sitting down with Jeffrey Singerman, who is the administrator and COO at Manhattan Endoscopy Center. Jeffrey, thanks for being here. To kick us off, can you share a little bit about yourself and your work in the ASC space?

0

54.723 - 79.583 Jeffrey Singerman

Sure. Good morning. So as you said, my name is Jeff Singerman. I am the chief operating officer slash administrator for Manhattan Endoscopy. We are a single specialty, non-hospital affiliated ASC located in Midtown Manhattan. We are GI specific. We have seven procedure rooms and should probably end the year with about 10,000 patients coming through the door.

0

80.221 - 100.677 Grace Lynn Keller

All right. Well, thanks for being here. And let's start our conversation with the ASC market, because in the U.S., this is projected to reach $60.8 billion by 2030, and it continues to experience strong year-over-year growth. From your perspective, what are the most significant trends in market forces driving this expansion, and how should ASC leaders be preparing today?

0

101.382 - 133.853 Jeffrey Singerman

So I think part of this trend is contributed to the cost base between the hospital, the hospital OPD, and the ASC. The cost base is much lower within the ASC environment. And our outcomes, I'm happy to say, are probably as good if not better than what goes on in the hospital. And then the second part that I think is contributing to this is that we can pivot from a technological standpoint

0

133.833 - 160.347 Jeffrey Singerman

much quicker than the larger health systems that have to go through layers and layers of bureaucracy to obtain what we can do in almost a instantaneous decision. From an administrator's standpoint or a COO's standpoint, I believe that you need to be flexible, open-minded, and evaluate what your ROI is going to be on any investment that you're going to make as this trend continues.

161.103 - 179.314 Grace Lynn Keller

Absolutely. And shifting gears slightly, from AI and robotic surgeries to advanced EHR systems, technology does remain a make or break factor and a critical driver of ASC operations at scale. So how do you see deeper tech integration shaping the way ASCs deliver care and manage their business over the next few years?

179.767 - 199.176 Jeffrey Singerman

So I kind of divide this into two different venues. I think one is a clinical venue and one is an administrative venue. So from a clinical standpoint, and we've gone through two, if not three tests of AI and its current iteration, it really has not helped in the GI environment.

199.595 - 223.02 Jeffrey Singerman

I think when we look out in 2030, I think where we'll probably see the most advances will be in polyp detection and possibly being able to look at when a gastroenterologist is doing histology in an area where their mucosal changes, that they conceivably determine if this is cancerous or not before it's ever removed from the body.

223.169 - 251.353 Jeffrey Singerman

But where I really see in 2030, and if not sooner, the impacts on the administrative side, which would ultimately, I believe, reduce staffing and help in the area of documentation from a physician standpoint as well, that they can meet the criteria that the insurance companies are putting up there to inhibit reimbursement or look for excuses to deny claims.

Comments

There are no comments yet.

Please log in to write the first comment.